Prakash Sunil, Chung Ki Wha, Sinha Srish, Barmada Michael, Ellis Demetrius, Ferrell Robert E, Finegold David N, Randhawa Parmjeet Singh, Dinda Amit, Vats Abhay
Department of Nephrology, Northern Railway Central Hospital, New Delhi, India.
J Am Soc Nephrol. 2003 Jul;14(7):1794-803. doi: 10.1097/01.asn.0000071513.73427.97.
Focal segmental glomerulosclerosis (FSGS) and Alport syndrome (AS) are two major causes of end-stage renal disease (ESRD). A few families with autosomal dominant FSGS have been reported with linkage to chromosome 19q13 or 11q22, while AS is usually linked to mutations in type IV collagen (COL4) subunit genes. A phenotype resembling AS may also be seen with myosin heavy chain-9 (MYH9) gene mutations. This study ascertained a multigeneration family (CHP-177) with clinical aspects of both FSGS and AS where we identified a new locus for the trait. A genome-wide scan was performed with 400 markers, and fine mapping was performed for chromosome 11 markers. Data were analyzed by GENEHUNTER and VITESSE under various models. CHP-177 is a 39-member kindred residing near New Delhi, India, with seven affecteds and showed male-to-male transmission. Two members had ESRD. Renal biopsies showed both FSGS lesions and thin glomerular basement membranes. Five of the affecteds also had sensorineural deafness, which involved both low and high frequency in some members. The AS loci, i.e., COL4A3/COL4A4 and MYH9 (LOD scores: -6.1 and -4.3, respectively) and FSGS loci, on 19q13 and 11q22, were excluded from linkage. A significant evidence of linkage was observed for 11q24 region, with a multipoint LOD (z-score) of 3.2 for marker D11S4464 at theta = 0. The z-1 confidence interval for the linked region spans a genetic distance of 7 cM. This study thus reports an autosomal dominant nephropathy with features of both FSGS and AS in which linkage to currently known loci for such phenotypes was excluded and a new locus on 11q24 was identified. The findings suggest further locus heterogeneity for the autosomal dominant nephropathy phenotype.
局灶节段性肾小球硬化(FSGS)和Alport综合征(AS)是终末期肾病(ESRD)的两大主要病因。已有少数常染色体显性FSGS家族报道其与19号染色体q13或11号染色体q22存在连锁关系,而AS通常与IV型胶原(COL4)亚基基因突变有关。肌球蛋白重链9(MYH9)基因突变也可能出现类似AS的表型。本研究确定了一个具有FSGS和AS临床特征的多代家族(CHP - 177),在此家族中我们鉴定出了该性状的一个新位点。使用400个标记进行了全基因组扫描,并对11号染色体的标记进行了精细定位。数据在不同模型下通过GENEHUNTER和VITESSE进行分析。CHP - 177是一个居住在印度新德里附近的39人亲属家族,有7名患者,呈男性对男性的遗传传递。两名成员患有ESRD。肾活检显示既有FSGS病变又有薄肾小球基底膜。5名患者还患有感觉神经性耳聋,部分成员的耳聋涉及低频和高频。排除了AS位点,即COL4A3/COL4A4和MYH9(对数优势分数:分别为 - 6.1和 - 4.3)以及19q13和11q22上的FSGS位点的连锁关系。在11号染色体q24区域观察到显著的连锁证据,标记D11S4464在θ = 0时的多点对数优势(z分数)为3.2。连锁区域的z - 1置信区间跨越7厘摩的遗传距离。因此,本研究报告了一种具有FSGS和AS特征的常染色体显性肾病,排除了与目前已知此类表型位点的连锁关系,并在11号染色体q24上鉴定出一个新位点。这些发现提示常染色体显性肾病表型存在进一步的位点异质性。